

# PRODUCTS BUSINESS REVIEW

## Anticipated Regulatory Approval Process and Estimated Launch Dates

| Product                           | Preclinical   | Phase 1 | Phase 2 | Phase 3 | Est Launch                                 | Market Size             | Planned Regulatory Approval Process  |
|-----------------------------------|---|---------|---------|---------|--|-------------------------|--|
| BioScavenger                      | Manufacture of clinical materials at commercial scale in 2016                               |         |         |         | 2017 <sup>(1)</sup><br>2020 (prophylactic) | \$0.5B <sup>(2)</sup>   | Emergency needs exemption<br><br>Repeat of Phase I then Phase II/III ("animal rule") |
| Intravenous Immunoglobulin (IVIg) | Preclinical testing complete. Manufacturing process finalized. IND filing planned for 2016. |         |         |         | 2018                                       | US\$6.8B <sup>(3)</sup> | 40 person single-arm clinical trial confirmed with FDA                               |
| Human Serum Albumin (HSA)         | In development  |         |         |         | 2018                                       | US\$2.0B <sup>(3)</sup> | No clinical trial requirement  |
| Alpha-1 Antitrypsin (AAT)         | In development  |         |         |         | 2020                                       | US\$0.6B <sup>(4)</sup> | Approval through bioequivalence trial  |
| Other Plasma Proteins             | Assessing target proteins   |         |         |         | 2020+                                      | US\$5.8B <sup>(4)</sup> | To be determined   |
| TBI 302 (Liver Cancer)            | IND Approved  |         |         |         | NA   | US\$1.3B <sup>(5)</sup> | Phase I to commence 2016   |
| TBI 304H (Anemia)                 | IND Approved  |         |         |         | NA   | US\$0.7B <sup>(5)</sup> | Phase I to commence 2016   |

1) Early launch through Treatment IND or Emergency Use Authorization (EUA)  
 2) Market size estimate conducted by an independent third party (includes pre- and post-exposure treatments) and assumes expected product profile is achieved  
 3) "The Worldwide Plasma Proteins Market 2012 (as revised September 15, 2014)" (2013): The Marketing Research Bureau Inc. at p. 11-12, ("MRB 2012 Worldwide")  
 4) MRB 2012 Worldwide at p. 9  
 5) Management estimate - see disclosure under heading "Products" on p. 34 of the Prospectus